Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Angiostatin endostatin gene therapy - Oxford BioMedica

Drug Profile

Angiostatin endostatin gene therapy - Oxford BioMedica

Alternative Names: Angiostatin lentivector gene therapy; EIAV.angiostatin - Oxford bioMedica; EIAV.endostatin - Oxford BioMedica; Endostatin lentivector gene therapy; OXB-201; RetinoStat

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 04 Dec 2017 Angiostatin endostatin gene therapy is still in phase I development in Age-related-macular-degeneration(In the elderly, In adults) in USA (Intravitreous, Injection) (Oxford BioMedica pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(In the elderly, In adults) in USA (Intravitreous, Injection)
  • 10 Oct 2016 Efficacy, adverse events and pharmacokinetics data from a phase I trial in wet Age related macular degeneration released by Oxford Biomedcia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top